In 2013 Pat Boyle was diagnosed with a grade III brain tumor, anaplastic astrocytoma. He had a successful surgery in June at Colombia Presbyterian Hospital. The next months were filled with recovery, radiation and chemotherapy treatments.
In the fall of 2015 Pat was diagnosed with a second brain tumor and was treated with radiation and chemotherapy treatments. In January of 2016 Pat had complications from treatment of the second tumor that led to severe cognitive defecits. Pat fought long and hard for 8 months following these complications. On September 15th 2016 Pat passed away at home surrounded by his loved ones.
We are asking our family and friends to walk again this year in memory of Pat and to donate to this important cause. Thanks for thinking of us and keeping us in your thoughts and prayers.
Each day 500 people will be diagnosed with a brain tumor. This is why I will be participating in the American Brain Tumor Association’s Breakthrough for Brain Tumors 5K Run & Walk. Each year, the Breakthrough for Brain Tumors 5K Run & Walk provides critical funding for brain tumor research and for supportive patient care.
We are participating and fundraising to maintain and strengthen the critical resources that make such a profound difference in the lives of brain tumor patients and their families.
You can support us in our efforts and in memory of Pat by making a donation to the American Brain Tumor Association.
Click on the Make a Donation! or the Support button by my Fundraising Meter to donate safely and securely online.
Your donation not only supports brain tumor patients and their families but it also supports the breakthrough research to improve, extend and ultimately save lives.
If you prefer to mail your donation, download the donation sheet under the donor info tab.
And remember, your donation is tax-deductible! You can learn more about the American Brain Tumor Association at www.abta.org.
Thank you in advance for your support of my efforts on behalf of brain tumor patients, their families and the researchers pursuing the breakthroughs.